The QualityStocks Daily Monday, April 1st, 2024

Today's Top 3 Investment Newsletters

MarketClub Analysis(VSTE) $7.9600 +157.61%

QualityStocks(ABIT) $0.1940 +44.82%

TradersPro(IMCC) $0.7421 +40.02%

The QualityStocks Daily Stock List

Athena Bitcoin Global (ABIT)

We reported earlier on Athena Bitcoin Global (ABIT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Athena Bitcoin Global (OTC: ABIT) is a digital asset tech firm that operates a network of cryptocurrency ATMs in North America and South America.

The firm has its headquarters in Chicago, Illinois and was incorporated in 1981, on August 26th by Sam Sesay. Prior to its name change, the firm was known as GamePlan Inc. It operates as part of the securities and commodity contracts intermediation and brokerage industry. The firm has two companies in its corporate family and serves consumers around the globe.

The company mines cryptocurrencies, with a focus on the generation of digital assets and the blockchain ecosystem. Its objective is to build open financial systems that serve the global community. The company’s solutions allow the opportunity and freedom to invest, spend, build and save.

The enterprise has developed a financial platform known as Athena RURU, which facilitates the use of digital currencies and electronic banking to power economies. Its peer-to-peer exchanges, i.e. and, allow individuals to sell and buy bitcoin and bitcoin cash without using an ATM. The enterprise also offers advisory services on a range of fixed income and equity transactions for real estate developers and firms. Its Bitcoin locations include El Salvador, Colombia, Argentina, Texas, Puerto Rico, Pennsylvania, Ohio, Missouri, Michigan, Illinois, Georgia, Florida, California and Alabama. The enterprise also operates a foundation for middle school and high school students.

The firm is focused on building alliances for a better financial world, which will not only bring in more opportunities for investment and growth but also benefit its shareholders.

Athena Bitcoin Global (ABIT), closed Monday's trading session at $0.194, up 44.8193%, on 843,616 volume. The average volume for the last 3 months is 950,983 and the stock's 52-week low/high is $0.0402/$0.44.

Brainstorm Cell Therapeutics (BCLI)

QualityStocks, Streetwise Reports, Wall Street Resources, MarketBeat, MarketClub Analysis, StockMarketWatch, AllPennyStocks, FeedBlitz, StreetInsider, The Street, TraderPower, Emerging Markets, Market Report, OTCPicks, Penny Invest, BUYINS.NET, Pumps and Dumps, StockEgg, StockMister, BullRally, Trades Of The Day, CoolPennyStocks, TradersPro, FreeRealTime, HotOTC, PennyStocks24, Stock Stars, SmallCap Network,, Stock Rich, OTC Advisors, Stock Fortune Teller, Stock Beast, SmallCapVoice, SmallCap Sentinel and IRGnews Alert reported earlier on Brainstorm Cell Therapeutics (BCLI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) (FRA: GHDN) is a biotechnology firm that is focused on developing and commercializing autologous cell therapies to treat neurodegenerative ailments.

The firm has its headquarters in New York and was incorporated in 2000, on September 22nd. Prior to its name change in November 2004, the firm was known as Golden Hand Resources Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company is dedicated to defeating neurodegenerative illnesses using its innovative technology platform dubbed NurOwn. It is party to a partnership agreement with Catalent, which entails the manufacture of NurOwn, which has been designed to develop new adult stem cell therapies for various indications.

The enterprise is involved in the development of NurOwn, which is in phase 2 clinical trials evaluating its effectiveness in treating Alzheimer’s disease and progressive multiple sclerosis. This technology has also concluded phase 3 clinical trials testing its efficacy in treating amyotrophic lateral sclerosis, which is a progressive nervous system illness that affects nerve cells in the spinal cord and brain, leading to a loss in muscle control.

The firm is focused on advancing its NurOwn technology, which it holds the right to develop and commercialize. This is in addition to positioning itself for sustained success by addressing the urgent unmet needs of patients with amyotrophic lateral sclerosis and providing broad patient access once its technology is approved.

Brainstorm Cell Therapeutics (BCLI), closed Monday's trading session at $0.7399, up 31.0253%, on 1,460,038 volume. The average volume for the last 3 months is 8,715 and the stock's 52-week low/high is $0.134/$3.43.

Dawson Geophysical (DWSN)

InvestorPlace, StockOodles, Motley Fool Hidden Gems, MarketBeat,, QualityStocks, StreetInsider, Zacks, TradersPro, Daily Profit, TradingMarkets, Turn Key Oil, Investment House, Greenbackers, Daily Trade Alert and Penny Stock Treasure reported earlier on Dawson Geophysical (DWSN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dawson Geophysical Company (NASDAQ: DWSN) (FRA: RVS1) is focused on providing onshore seismic data processing and acquisition services.

The firm has its headquarters in Midland, Texas and was incorporated in 1952 by L. Decker Dawson. Prior to its name change, the firm was known as TGC Industries Inc. It serves consumers in Canada and the United States. The firm generates the majority of its revenue from the United States.

The company operates through the contract seismic data acquisition and processing segment. It acquires and processes multi-component, three-dimensional and two-dimensional seismic data for its clients, which include independent gas and oil operators, gas and oil companies and providers of multi-client data libraries. The company has approximately ten seismic crews that provide seismic data mainly to firms engaged in the development and exploration of natural gas and oil on land. Two of these crews are based in Canada with the remaining being based in the U.S.

The enterprise provides magnetic and gravity data; processing services, support services, field operation services and project management services, as well as planning and design services. It also offers multi-component seismic data surveys, which involve recording of alternative seismic waves. The enterprise owns equipment for more than twenty land-based seismic data acquisition crews, including about twenty central recording systems, more than 245,000 recording channels and roughly 220 vibrator energy source units. It also provides its services to the potash mining industry.

The firm is committed to its strong Health, Safety and Environmental program and is focused on further improving its drilling and completion activities. Providing high quality services helps to retain existing customers and attract new ones, which may bring in more investors into the firm, thus boosting its growth.

Dawson Geophysical (DWSN), closed Monday's trading session at $1.71, up 20.4225%, on 124,753 volume. The average volume for the last 3 months is 92,083 and the stock's 52-week low/high is $1.27/$2.6513.

Affimed NV (AFMD)

MarketClub Analysis, MarketBeat, StockMarketWatch,, QualityStocks, PoliticsAndMyPortfolio, TradersPro, BUYINS.NET, StreetInsider, Schaeffer's, Trading Concepts, Barchart, FreeRealTime, Investment U, InvestorPlace, OTCtipReporter, PennyStockScholar, Wall Street Mover, Profitable Trader Authority, Stock Beast, The Online Investor and PennyStockProphet reported earlier on Affimed NV (AFMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Affimed NV (NASDAQ: AFMD) is a clinical-stage biopharmaceutical firm that is engaged in the discovery and development of cancer immunotherapies.

The firm has its headquarters in Heidelberg, Germany and was incorporated in 2000. Prior to its name change in October 2014, the firm was known as Affimed Therapeutics B.V. It serves consumers around the globe, with a focus on Germany, Europe and the United States. The firm generates the majority of its revenue from the United States.

The company is party to collaboration agreements with Roche Holding AG, Roivant Sciences Ltd, Genentech Inc., and the University of Texas MD Anderson Cancer Center. It also has a research funding agreement with the Leukemia & Lymphoma Society. The company is focused on providing a unique approach to fighting cancer using its scientific team, which has extensive expertise in immunity and cell engager-based medicines. Its objective is to overcome the challenges and limitations faced by the current immune-oncology therapies.

The enterprise’s product portfolio comprises of its AFM13 formulation, which in different phases of clinical trials evaluating its effectiveness in treating transformed mycosis fungoides, peripheral T-cell lymphoma, hodgkin lymphoma and CD30-positive T-cell lymphoma. It also develops a cell-engaging bi-specific antibody formulation dubbed AFM26, for the treatment of multiple myeloma, as well as its AFM24 formulation, which has been developed to treat advanced cancers.

The company is focused on progressing its parallel development strategy for some of its formulations and advancing its broad development pipeline, which it expects will generate an ongoing stream of data over the coming quarters.

Affimed NV (AFMD), closed Monday's trading session at $6.35, up 19.8113%, on 228,287 volume. The average volume for the last 3 months is 178,725 and the stock's 52-week low/high is $2.235/$11.10.

Imunon Inc. (IMNN)

We reported earlier on Imunon Inc. (IMNN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Imunon Inc. (NASDAQ: IMNN) (FRA: CBO) (LON: 0HUZ) is a clinical-stage biopharmaceutical firm that is focused on developing and commercializing DNA-based vaccines, immunotherapies and directed chemotherapies.

The firm has its headquarters in Lawreneceville, New Jersey and was incorporated in 1982 by Yim-Pan Cheung. Prior to its name change, the firm was known as Celsion Corp. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is focused on advancing a portfolio of innovative treatments which harness the body's natural mechanisms to generate effective, safe and durable responses across a broad array of human illnesses. It operates through the ThermoDox and Celsion brands.

The enterprise has developed a feasibility stage platform technology for the development of nucleic acid-based vaccines, immunotherapies and other anti-cancer DNA or RNA therapies dubbed TheraPlas; and its Placcine platform, which develops nucleic acid vaccines for cancer and other infectious illnesses. Its product pipeline is comprised of a DNA-based immunotherapy dubbed GEN-1, which has been developed to locally treat ovarian cancer. It also develops a proprietary heat-activated liposomal encapsulation of doxorubicin known as ThermoDox, which is in the development stage for a range of cancer indications.

The company, which recently provided a business update, remains focused on advancing its pipeline, whose success and approval will bring in additional revenues and investments into the firm. This is in addition to benefiting patients with various indications and generating value for its shareholders.

Imunon Inc. (IMNN), closed Monday's trading session at $1.93, up 17.6829%, on 430,898 volume. The average volume for the last 3 months is 72,016 and the stock's 52-week low/high is $0.48/$2.00.

Gatekeeper Systems (GKPRF)

InvestorPlace, Trades Of The Day and QualityStocks reported earlier on Gatekeeper Systems (GKPRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gatekeeper Systems Inc. (OTC: GKPRF) (CVE: GSI) (FRA: 1GK) is a company focused on designing, manufacturing, marketing and selling video security solutions for extreme and mobile environments.

The firm has its headquarters in Abbotsford, Canada and was incorporated in 1997 by Douglas A. Dyment. It operates as part of the security and protection services industry, under the industrials sector. The firm primarily serves consumers in Canada and the United States.

The enterprise’s offerings include the AI Dash Cam, an AI-based dash cam that offers driver status monitoring and advanced driver assistance systems; G4 Viewer, which revolutionizes video management for fleet monitoring; and CLARITY, an integrated video and passenger counting school bus operating platform. It also offers Automated Lane Enforcement, a video and data analytics solution that provides automatic enforcement of transit lane violations; interior and exterior cameras, and mobile data collectors; and wireless systems, such as access points, yard guards, mobile wireless modules, and mobile Wi-Fi systems. This is in addition to providing a health monitoring panel that measures the body temperature of individuals entering a transportation vehicle or building; a school bus student protector solution that automatically enforces stop-arm violations; and an intelligent temperature sensing system. Further, the enterprise offers on-site system maintenance and repair, testing, troubleshooting, system installation, training, and warranty support services. It serves the transit, school bus, police, ambulance, taxi, and transport markets.

The company recently announced its latest financial results showing significant increases in its revenues. It remains focused on growing the school and transit segments of its business and generating additional shareholder value.

Gatekeeper Systems (GKPRF), closed Monday's trading session at $0.59965, up 3.3879%, on 77,172 volume. The average volume for the last 3 months is 1.886M and the stock's 52-week low/high is $0.1471/$0.61.

Aurora Cannabis Inc. (ACB)

InvestorPlace, Schaeffer's, MarketBeat, StocksEarning, MarketClub Analysis, The Street, QualityStocks, Trades Of The Day, StockEarnings, Daily Trade Alert, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, Kiplinger Today, StockMarketWatch, CFN Media Group, Investopedia, Stock Up Featured, Profit Trends, BUYINS.NET, BlackSwanAlert, StreetAuthority Daily, The Rich Investor, Jim Cramer, Early Bird, Investors Alley, Cannabis Financial Network News, Wall Street Window, CNBC Breaking News, Daily Profit, Tradespoon, Inside Trading, Outsider Club, TheTradingReport, Zacks, The Wealth Report, Market Intelligence Center, Technology Profits Daily, Money and Markets and Top Pros' Top Picks reported earlier on Aurora Cannabis Inc. (ACB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A panel reviewing Canadian law on adult-use marijuana has recommended that pharmacy access be enabled for medical cannabis. This comes after Shoppers Drug Mart, the biggest pharmacy chain in the nation, requested that pharmacies be allowed to sell medical marijuana products.

By doing so, patient concerns on product shortages and delays in delivery could be addressed. Additionally, enabling this access would allow patients to freely consult with pharmacists on side effects and drug interactions at their own convenience.

The Cannabis Act, which legalized recreational marijuana, established a legal framework for producing, distributing, selling and possessing marijuana across Canada.

The panel, which was appointed by the government, also gave other recommendations, including maintenance of the current limit of THC for edibles. This suggestion was deemed a bit controversial as the current cap stands at 10mg, yet illicit edibles contain almost 100 to 200 times this limit.

It also suggested that the overall excise tax model be reviewed, noting that the average price of marijuana since legalization had decreased greatly, resulting in greater excise payments as sales percentages.

The panel also proposed that products with higher delta-9 THC potency have a higher tax imposed on them in comparison to lower-potency products. The goal of this was to discourage individuals from consuming higher-risk marijuana products and reduce their proliferation.

In addition, the panel suggested that an excise tax-sharing framework with First Nations be developed. It also admitted to the existence of challenges and barriers that faced Inuit, First Nations and Metis entrepreneurs and communities.

Chair Morris Rosenberg stated in the report that the issues had caused public-safety and public-health challenges in different communities. He explained that there was a critical need to look into these issues in an effort to protect public safety and health while also recognizing the rights of Indigenous peoples.

It is important to note that none of the recommendations given are legally binding.

What is clear, however, is that the federal government needs to set aside needed resources and funding to make sure that the marijuana framework is effectively implemented. Currently, the federal government employs hundreds to regulate the drug. This makes it an expensive system to maintain.

Some hope that some suggestions shall be considered for the next federal budget, which will be announced next month. This comes after the standing committee under the House of Commons recommended that duty be limited to a 10% ad valorem rate.

The proposed changes to Canadian marijuana law are issues that entities such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) would be interested in because nearly all jurisdictions where marijuana is legal would benefit from such changes.

Aurora Cannabis Inc. (ACB), closed Monday's trading session at $4.31, off by 1.8223%, on 3,960,165 volume. The average volume for the last 3 months is 42.941M and the stock's 52-week low/high is $2.84/$11.50.

Rivian Automotive Inc. (RIVN)

InvestorPlace, Schaeffer's, The Street, QualityStocks, Kiplinger Today, MarketBeat, MarketClub Analysis, Early Bird, INO Market Report, StockEarnings, Investopedia, The Online Investor, Zacks, GreenCarStocks, Daily Trade Alert, AllPennyStocks, Louis Navellier, StocksEarning, The Night Owl, TipRanks, Trades Of The Day, InvestorIntel, DividendStocks, InvestorsUnderground, Cabot Wealth, BillionDollarClub, 360 Wall Street, FreeRealTime, Top Pros' Top Picks, Top Pros’ Top Picks and bullseyeoptiontrading reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Japanese carmaker Nissan has set its sights on cutting the cost of producing battery electric vehicles by close to one-third by the end of the decade. The move is designed to help the company compete against Chinese manufacturers. The automaker sold a whopping 3.4 million cars worldwide in 2023 and is looking to boost its vehicle sales by an additional million units over the next three years.

Nissan’s plan to reduce electric vehicle production costs will involve launching 30 new models through 2026, with 16 of those being electric cars. If Nissan’s plan is successful, electric cars will account for 40% of its total vehicle sales by 2026 and up to 60% by the end of the decade, putting it on track to fully electrifying its vehicle lineup.

To cut vehicle production costs by 30% by the year 2030, Nissan will leverage next-gen modular manufacturing techniques and novel battery innovations while also group sourcing raw materials. Much like Nissan, several other automakers in Japan, Europe and the United States are keen on reducing electric vehicle manufacturing prices amid increasingly stiff competition from Chinese players.

Electric vehicle prices have been significantly higher than internal combustion engine (ICE) cars since the beginning of the EV industry, mostly due to high production costs. As EV components such as batteries are incredibly expensive to source and produce, most manufacturers pass these costs onto their consumers, resulting in much higher prices for EVs compared to similar ICE cars.

However, China’s government has spent the past several years providing billions of dollars’ worth of subsidies to local automakers, allowing the companies to minimize their production costs and sell EVs at much lower price points. These automakers have begun exporting their cheap electric cars to overseas markets, such as Europe, and are putting significant pressure on local carmakers to also cut prices just to remain competitive.

According to the EU Commission, Chinese electric cars tend to be at least 20% cheaper than their European-made counterparts, making it extremely difficult for European automakers to attract and retain customers. With Chinese automakers facing increased scrutiny in the European market due to their lower prices, these EV manufacturers could consider entering other markets such as Japan, where they still don’t have much concentration.

Nissan became one of the earliest adopters of EV technology when it debuted the Nissan Leaf more than a decade ago, but Chinese counterparts such as Li Auto and BYD have surpassed it in the EV segment. To remain competitive in the face of increased Chinese competition, Nissan will work to reduce EV production costs in many ways. This includes leveraging the Nissan Intelligent Factory concept in many of its production plants to reduce production time by up to one-fifth by relying on robots.

If Nissan succeeds in cutting the cost of producing its EVs, electric vehicle startups such as Rivian Automotive Inc. (NASDAQ: RIVN) will have stiffer competition to contend with in the industry, making the struggle for prominence in the space even harder.

Rivian Automotive Inc. (RIVN), closed Monday's trading session at $11.09, up 1.2785%, on 23,816,113 volume. The average volume for the last 3 months is 17.73M and the stock's 52-week low/high is $10.05/$28.06.

Meta Platforms Inc. (META)

The Street, Zacks, InvestorPlace, Early Bird, Investopedia, Schaeffer's, MarketClub Analysis, MarketBeat, The Online Investor, Kiplinger Today, INO Market Report, Cabot Wealth, Louis Navellier, TipRanks, The Night Owl, Top Pros' Top Picks, Money Wealth Matters, Trading Tips, The Daily Market Alert, TradersPro, AllPennyStocks, DividendStocks, Eagle Financial Publications, Investment House, Daily Wealth, Trading with Larry Benedict, InvestorIntel, The Wealth Report, Market Trends, Smartmoneytrading, CNBC Breaking News, FreeRealTime, Contrarian Outlook, InsiderTrades, Investing Breakout, TradingPub, Rick Saddler, Smart Investing Society, QualityStocks, The Stock Dork, bullseyeoptiontrading, Jon Markman’s Pivotal Point, TradeSmith Daily, Trade Out Loud,, Investing Daily, wyatt research newsletter, Chaikin Analytics, The SmartMoneyTrading, 360 Wall Street, The Investing Insider, Empire Financial Daily, empirefinancialresearch, Hit and Run Candle Sticks, Investor News, Inside Trading, Mind Over Markets, Trading Pub, Investor's Business Daily, 1 2 3 Trade Option, OTC Stock Review and iDigital Market reported earlier on Meta Platforms Inc. (META), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A London-based, deep-tech start-up recently raised $2.9 million in funding to train artificial intelligence to make decisions in the same way that human beings do. Stanhope AI, which has a robust background in robotics, neuroscience and fintech, was founded as an independent entity from University College London.

Renowned names in artificial intelligence research and neuroscience involved in its formation include Professor Rosalyn Moran (current CEO, active inference specialist); Professor Karl Friston of the UCL Queen Square Institute of Neurology (current director); and Dr. Biswa Sengupta (current technical advisor, specialized in dynamical systems, energy optimization and efficiency).

The start-up is pioneering a new AI generation technology called agentic artificial intelligence. It has designed an algorithm that, similar to the human brain, tries to guess what may happen next. This algorithm learns from any differences between actual and predicted events and updates its internal models.

Agentic AI models are also responsible for their own learning. They do this by continuously feeding themselves data generated in real-time from the environment through onboard sensors. This eliminates the need to train large language models to make decisions based on data observed.

Stanhope based this approach on active inference, a principle in neuroscience that discusses how our brains always make forecasts from sensory data obtained from our surrounding environment. Changes in data prompt the brain to adjust and update its forecasts in a bid to help refine how we view the world.

The start-up’s models and machines are smaller in size and use little energy to run, which makes it easier for them to be operated on small devices such as drones. This is a stark contrast to current machine-learning techniques used to train current artificial intelligence systems such as large language models.

Current models solely operate within the domains of the training given, which makes it hard for them to continuously learn and update their information. Additionally, they need a lot of observed data as well as high amounts of energy and processing power to run and train.

The company’s approach is also propped up by free energy as well as thorough research conducted by the team of founders. For instance, the free-energy theory principle coined by Friston focuses on how the human brain minimizes uncertainty and surprise.

The company remains focused on transforming AI’s capabilities and enhancing its impact in real-world scenarios. It also hopes to address some of the issues in AI today while also better understanding the science behind this technology.

The AI that Stanhope AI is looking to develop could be a technology that entities such as Meta Platforms Inc. (NASDAQ: META) would have plenty of use for — if they don’t come up with something themselves for their own products.

Meta Platforms Inc. (META), closed Monday's trading session at $491.35, up 1.1883%, on 9,247,007 volume. The average volume for the last 3 months is 4.157M and the stock's 52-week low/high is $207.13/$523.57.


InvestorPlace, Schaeffer's, StockEarnings, StocksEarning, QualityStocks, MarketBeat, Trades Of The Day, Daily Trade Alert, BUYINS.NET, Kiplinger Today, The Street, StreetInsider, The Online Investor, FreeRealTime, Early Bird, CNBC Breaking News, Investopedia, MarketClub Analysis, StockMarketWatch and MarketClub reported earlier on SNDL Inc. (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent study supported by federal funds has found no clear link between the legalization of cannabis for adult use and an increase in its consumption among middle schoolers.

To investigate the impact of legal sales on youth usage, researchers conducted a comparative analysis of middle-school usage rates in New Mexico and Nevada, utilizing data from state-conducted surveys in 2017 and 2019. Notably, during this period, Nevada permitted adult-use cannabis sales while New Mexico restricted its use to medical purposes only.

Across both states, the study uncovered rises in the percentages of middle schoolers who had experimented with marijuana and those who reported using it within the past month.

In Nevada, the proportion of students admitting to ever trying marijuana increased from 9.7% in 2017 to 13.3% in 2019. Similarly, past 30-day usage surged from 6.3% to 8.9%. Meanwhile, in New Mexico, lifetime usage rose from 14.1% to 17.4%, with past 30-day usage climbing from 8.9% to 10.5%.

Despite these concerning trends, researchers refrained from directly attributing the rise to legalization. They stated that they didn’t discover convincing evidence linking cannabis legalization with an immediate spike in use among middle school students in Nevada, which is consistent with earlier research.

However, they deemed the general rise in cannabis use among middle-schoolers in both New Mexico and Nevada within the said period troubling due to the known health risks associated with early initiation of cannabis use.

The study, which was supported by a grant from the National Institute on Drug Abuse (NIDA), involved cooperation between researchers from the New Mexico Health Department and the universities of New Mexico and Nevada. Analysis across the two states revealed that female students, individuals of nonwhite ethnicity and those attending low-income Title I schools exhibited higher likelihoods of both past 30-day and lifetime marijuana usage.

The authors suggested that their findings were consistent with existing literature, which suggests that cannabis usage might serve as a coping mechanism for discrimination and poverty, with adolescent females increasingly reporting higher usage rates compared to males.

In terms of policy implications, the study underscored the importance of targeting prevention efforts toward groups at heightened risk rather than solely focusing on the legal status of cannabis for adults.

However, the researchers acknowledged certain limitations of their study, including the inability to account for the potential influence of neighboring states with differing marijuana policies, such as California and Colorado. Additionally, the study did not delve into the frequency of usage or changes in marijuana use disorder.

Several studies have been published dispelling the misconception that cannabis legalization permitting companies such as SNDL Inc. (NASDAQ: SNDL) to operate results in more teens accessing marijuana products. The data is consistent in showing that this isn’t the case.

SNDL Inc. (SNDL), closed Monday's trading session at $1.97, off by 1.7456%, on 8,652,157 volume. The average volume for the last 3 months is 671,700 and the stock's 52-week low/high is $1.25/$2.36.

Alta Global (MMA)

We reported earlier on Alta Global (MMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alta Global (NYSE American: MMA) is reporting on the pricing of its initial public offering. The offering consists of 1,300,000 ordinary shares at $5 per share. The offering, which is expected to close on April 2, 2024, is estimated to result in $6.5 million in gross proceeds before standard deductions and expenses. The announcement also noted that Alta Global granted the underwriters a 45-day option to purchase up to an additional 195,000 ordinary shares; the option was granted to cover any overallotments at the public offering price. A technology company, Alta Global is enabling the global martial arts and combat sports industry to maximize the monetization opportunities available by increasing consumer participation in the sport and building upon existing community offerings within the sector. According to the announcement, Alta Global plans to use the funds from the public offering for marketing and sales, product development, research and development, and other general corporate purposes including working capital, operating expenses and capital expenditures. ThinkEquity is acting as sole book-running manager for the offering.

To view the full press release, visit

About Alta Global Group Limited

Alta Global Group Limited is a technology company that is enabling the global martial arts and combat sports industry to maximize the monetization opportunities available to the sector by increasing consumer participation in the sport and building upon existing community offerings within the sector. While the company believes martial arts and combat sport gyms have a superb in-gym product, they are ripe for transformation when it comes to building sales channels, enhancing customer onboarding, optimizing engagement and driving the growth and retention of members and membership revenues within their gym communities. For more information about the company, please visit

Alta Global (MMA), closed Monday's trading session at $3.7499, off by 10.2895%, on 68,553 volume. The average volume for the last 3 months is 1.592M and the stock's 52-week low/high is $3.59/$5.25.

Applied UV (AUVI)

QualityStocks, StreetInsider, MarketClub Analysis, FreeRealTime, The Stock Dork, The Online Investor, Small Caps, InvestorsUnderground, Broad Street, INO Market Report, MarketBeat, OTCtipReporter, Profitable Trader Authority, TradersPro, Schaeffer's, The Wealth Report and PennyStockScholar reported earlier on Applied UV (AUVI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied UV (NASDAQ: AUVI), a leader in smart building technology solutions, has closed on a registered direct offering as well as a concurrent private placement with institutional investors. According to the announcement, Applied UV issued shares of common stock and prefunded warrants in a registered direct offering. In addition, the company also issued common warrants to the same investors in a concurrent private placement. It is estimated that gross proceeds from both transactions, which closed today, will total approximately $2.76 million. The company noted that the transactions consisted of the public sale of 1,726,875 shares of common stock (or prefunded warrants in lieu thereof) as well as the private placement of common warrants to purchase up to 518,065 shares of common stock. “The prefunded warrants will be immediately exercisable and may be exercised at any time until exercised in full,” according to the announcement. “The common warrants are exercisable immediately subject to registration and expire five years after the initial issuance date. The company expects to use the net proceeds from the offering to help fund recent large orders within the Smart Building Technologies division from customers including Siemens, Sherwin Williams and Arco Murray and other general corporate purposes.”

To view the full press release, visit

About Applied UV Inc.

Applied UV is dedicated to developing and acquiring smart building technologies for healthcare, hospitality, commercial and municipal markets. With SteriLumen, MunnWorks, LED Supply Co. and PURO, the company has a diverse portfolio that addresses various needs in the market. Applied UV is committed to innovation and excellence in providing solutions for a healthier and smarter world. For more information about Applied UV, please visit

Applied UV (AUVI), closed Monday's trading session at $1.24, off by 16.7785%, on 289,476 volume. The average volume for the last 3 months is 764,623 and the stock's 52-week low/high is $1.22/$105.00.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

The world's increasing emphasis on green energy has led to the emergence of a practice called "agrivoltaics," which combines sustainable agriculture with renewable energy. With the global population reaching 8 billion in late 2022, food production is becoming an increasingly important industry. However, the food supply chain produces roughly 9,800 to 16,900 million tons of carbon dioxide every year, and its emissions are projected to reach 30% by 2050. To make food production sustainable, farmers in many nations are combining farming with clean renewable energy. While Adapture Renewables is focusing on the generation of green energy in a way that puts their sites to maximum use, other entities are also devoting their energies to fighting climate change in a different way. For example, Mullen Automotive Inc. (NASDAQ: MULN) is focused on EVs to make transportation possible without using fossil fuels such as gasoline.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has filed for Foreign Trade Zone ("FTZ") status with the U.S. Department of Commerce; the company is filing for the status at its commercial vehicle manufacturing and assembly center in Tunica, Mississippi. According to the announcement, the company anticipates that FTZ status would provide key benefits, including the opportunity for improving company cash flow through reduction of taxes, fees and deferment of import duties. Specifically, Mullen projects that deferred working capital on domestic sales could result in deferred capital outlays of $10 million for the remainder of fiscal year 2024. A Foreign-Trade Zone is a secure area within the United States where foreign and domestic merchandise is generally considered to be in international commerce and outside of U.S. customs territory for duty and tariff purposes. "Achieving FTZ approval status is an important strategic initiative to further strengthen Mullen's supply-chain management and deliver significant cash-flow savings," said Mullen Automotive CEO and chair David Michery in the press release. "As we continue to expand our distribution internationally, the FTZ would provide a competitive advantage with no duties or tariffs paid on sales outside of the U.S."

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $5, off by 3.8462%, on 731,464 volume. The average volume for the last 3 months is 82 and the stock's 52-week low/high is $4.11/$3125.25.

Recent News

Sigyn Therapeutics Inc. (OTCQB: SIGY)

The QualityStocks Daily Newsletter would like to spotlightFathom Sigyn Therapeutics Inc. (OTCQB: SIGY).

Sigyn Therapeutics CEO Jim Joyce reviewed the company's pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States

The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies

Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively

To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells

Sigyn Therapeutics (OTCQB: SIGY), a San Diego-headquartered medical technology company that creates medical solutions to treat life-threatening conditions, took part in the recent Emerging Growth Conference, with CEO Jim Joyce giving a live online presentation and updating attendees on the company's portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare (

Sigyn Therapeutics Inc. (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy™ to address pathogen-associated inflammatory disorders, the ImmunePrep™ platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep™ to improve the delivery of cancer chemotherapy and ChemoPure™ to reduce the toxicity of chemotherapy.

Sigyn created each of these technologies with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in healthcare, and 2) their successful clinical advancement would offer a potential competitive advantage to established therapeutic organizations.

Sigyn Therapy™

The company is advancing Sigyn Therapy™ to treat pathogen-associated inflammatory disorders that are not addressed with FDA approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia and sepsis, which is the leading cause of hospital deaths in the United States.

The technology has the following attributes and capabilities.

  • Sigyn Therapy™ incorporates a formulation of adsorbent components that have more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove therapeutic targets from the bloodstream.
  • In vitro studies have demonstrated the ability of Sigyn Therapy™ to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma. In these studies, 12 relevant targets, including viral pathogens, bacterial toxins and inflammatory cytokines, were validated. Subsequent animal studies were completed at the University of Michigan.
  • Sigyn Therapy™ is highly efficient, as the entire circulatory system of a patient can pass through the device ~15-times during a four-hour treatment.
  • To allow for broad deployment, Sigyn Therapy™ is designed for use on the established infrastructure of dialysis and continuous renal replacement machines already located in hospitals and clinics around the world.

First-in-human studies of Sigyn Therapy™ plan to enroll dialysis dependent end-stage renal disease (ESRD) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. There are more than 550,000 individuals with ESRD in the United States, which result in approximately 85 million dialysis treatments being administered each year.

The ImmunePrep™ Platform

Immunotherapeutic antibodies to treat cancer are among the most valued assets in global medicine. However, these drugs suffer from a severe limitation: they are poorly delivered to cancer cell targets, and, as a result, a majority of patients do not respond to therapy.

The Sigyn team recognized that just a small fraction of an antibody dose reaches its cancer cell target, yet a significant portion of the same dose can be sequestered by circulating decoys that display the target (antigen) binding site of the antibody. In response, Sigyn designed the ImmunePrep™ platform to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody.

The company believes its reverse decoy mechanism will increase the availability of antibodies to interact with their intended disease targets, and, simultaneously, the devices will also extract disease targets from the bloodstream to further improve patient benefit.

The opportunity to enhance the performance of therapeutic antibodies is significant. Consider that Pfizer’s $43 billion acquisition of Seagen Inc. and Amgen’s $27.8 billion acquisition of Horizon Therapeutics were the highest valued M&A deals of 2023. In both cases, transaction values were driven by market-cleared antibody assets.

Perhaps more revealing were the values placed on clinical-stage (pre-revenue) therapeutic antibody candidates. In this regard, consider Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7 billion acquisition of a clinical-stage antibody from Roivant Sciences.

In the backdrop of these M&A transactions, the immune checkpoint antibody Keytruda (Merck) became the world’s best-selling (non-vaccine) drug in 2023, with anticipated revenues of ~$24 billion.

ChemoPrep™ and ChemoPure™

Recent scientific publications have reported that only 1% of chemotherapy is delivered to the tumor cell targets of cancer patients. In response, the Sigyn team designed ChemoPrep™ to overcome a delivery limitation of the most commonly administered drug to treat cancer.

The company is developing ChemoPrep™ to reduce the circulating presence of tumor-derived exosomes (tumor exosomes), which interfere with chemotherapy delivery. High concentrations of tumor exosomes in the bloodstream correspond with poor treatment outcomes, whereas low concentrations of tumor exosomes correspond with more favorable outcomes. As compared to non-cancer subjects, exosome populations are reported to be 10x to 500x higher in the bloodstream of cancer patients. Based on these factors, the company believes there is a compelling scientific rationale to reduce the circulating presence of tumor exosomes prior to chemotherapy administration.

Inversely, the Sigyn team recognized that if 99% of chemotherapy was missing its target, then there was a need to eliminate off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage. This factor led to the design of ChemoPure™ to reduce treatment toxicity by reducing the presence of off-target chemotherapy from the bloodstream. The company believes that a reduction in chemotoxicity may also alleviate treatment-related fatigue and potentially temper the long-term health consequences associated with chemotherapy administration.

Management Team

James A. Joyce is Co-Founder, Chairman and CEO of Sigyn Therapeutics. He has more than two decades of public company CEO and corporate board leadership experience and is an inventor or co-inventor of 20 pending or issued patents, including those underlying ImmunePrep, ChemoPrep, ChemoPure and Sigyn Therapy. Previously, he was founder and CEO of Aethlon Medical, a therapeutic technology company that he built from a start-up to a Nasdaq-traded company. Under his leadership, Aethlon developed the first medical device to receive two breakthrough device designations from the FDA. Mr. Joyce graduated from the University of Maryland.

Annette Marleau, Ph.D., is Chief Scientific Officer at Sigyn Therapeutics. Prior to joining the company, she was Chief Technology Officer at Immunicom Inc. and Director of Research at Aethlon Medical Inc. Additionally, she is an inventor on pending and issued patents underlying blood purification therapies targeting cancer, inflammatory disorders and life-threatening infectious diseases. She holds a Ph.D. from Western University, an M.S. from the University of Guelph and a B.S. from the University of Waterloo in Canada.

Jerry DeCiccio, CPA, is CFO at Sigyn Therapeutics. He has more than 40 years of financial industry experience. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications and President at Cerebain Biotech Corp. He also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc. and Newport Corp. He earned a bachelor’s degree in accounting and business administration from Loma Linda University and an MBA in finance and systems technology from the University of Southern California.

Sigyn Therapeutics Inc. (OTCQB: SIGY), closed Monday's trading session at $5.5, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $3125.25/$.

Recent News

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

The global solar energy market is forecasted by Fortune Business Insights to rise from $3.33 billion in 2022 to over $20 billion by 2030

Turbo Energy S.A. will be part of the explosive growth, as tech-infused photovoltaics become instrumental in more efficient use of solar energy

Turbo Energy S.A. is a leader in the residential markets in Spain, offering a complete lineup of Li-ion batteries, inverters, software, and their turnkey product, Sunbox

The world is facing a critical juncture. Our dependence on fossil fuels has demonstrably contributed to climate change, necessitating a global shift towards cleaner, more sustainable energy sources. Solar energy, harnessed through photovoltaic ("PV") technology, offers a promising solution. However, to truly unlock its potential and pave the way for a more sustainable future, advancements in technology are crucial. The answer resides in the exciting world of tech-infused photovoltaics, the path towards widespread solar harvesting and energy management, and the potential role Turbo Energy (NASDAQ: TURB) can play in this revolution.

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.


Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.


The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Monday's trading session at $1.14, off by 0.869565%, on 4,359 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.855/$7.90.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave will release its financial results for the fourth quarter and fiscal year 2023 before market open on Thursday, March 28, 2024

D-Wave will host a conference call on March 28, 2024, at 8:00 a.m. (Eastern Time) to address the company's financial performance and strategic outlook

CEO Alan Baratz and CFO John Markovich will participate in the conference call discussion

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, recently announced the scheduled release of its financial results for the fourth quarter and fiscal year 2023, which concluded on December 31, 2023. The release is set for Thursday, March 28, before the market opens. Interested parties can access the press release via the D-Wave Investor Relations website:

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $1.99, off by 2.451%, on 4,201,877 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3962/$3.20.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

A new study has found that caffeine exposure during pregnancy and a high-fat diet following delivery considerably heightens the risk of autism-like behaviors, as observed in rodent models. Autism spectrum disorder is a developmental disorder that influences how individuals interact, behave, learn and communicate. Children with this condition may have trouble with social interactions as well as display repetitive behaviors, among other symptoms. Given that caffeine consumption and high-fat diets are widespread, it is important to understand possible risk factors and develop strategies to prevent the disorder's development. These findings give insight into the links between neurodevelopmental disorders, prenatal environmental exposures and diet. The results were published in "Ecotoxicology and Environmental Safety." With enterprises such as PaxMedica Inc. (NASDAQ: PXMD) working to bring effective autism spectrum disorder treatments onto the market, patients could have a brighter future in the not-so-distant future.

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Monday's trading session at $0.549, up 7.6471%, on 142,428 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.372/$38.9283.

Recent News

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Goldman Sachs Group is predicting a surge in commodity prices in 2024 as central banks across the United States and Europe work to reduce interest rates in their respective countries that would likely support both consumer and industrial demand. According to a March 24, 2024, note, raw materials could see a return of up to 15% through the year as the cost of debt reduces, the manufacturing sector starts to recover and global geopolitical risks with the potential to affect commodity prices persist. Several Goldman analysts, including Daan Struyven and Samantha Dart, believe that oil, gold, aluminum and copper products may see a rise in prices. But the analysts warned investors to be selective with their investments as the commodities' gains would not be universal. Goldman Sachs analysts said they would maintain a constructive view of gold in the midterm as the Fed will inevitably ease its monetary policy, potentially resulting in renewed buying in the mostly dormant ETF space. Mineral exploration companies such as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) are likely to be banking on future increases in the current prices of commodities because they invest in taking prospective mines to the production phase.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.


Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Monday's trading session at $1.55, up 6.3465%, on 59,289 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.21/$3.40.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Earlier this month, Representative Greg Murphy reintroduced an amended measure in Congress that would prevent retirement plan trustees from investing in environmental, social and governance ("ESG") on behalf of participants and beneficiaries. The measure, which was advanced to the House Ways & Means Committee, was cosponsored by Reps. Beth Van Duyne, Claudia Tenney and Mike Kelly. In a statement, Murphy explained that tax-advantaged retirement plans helped people save for their retirement and therefore needed to be managed in a way that would bring in the most returns instead of investing in risky ventures. He noted that unstable investments could be pursued independently but not with funds from millions awaiting retirement. A number of initiatives seeking to endorse ESG investing in retirement plans or restrict it have been introduced in both the Senate and the House of Representatives. This negative response to ESG doesn't seem to be discouraging businesses such as Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) from moving forward with their implementation of the principles espoused by the ESG movement.

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $3.39, up 21.9424%, on 171,508 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.38/$8.90.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is reporting on its financial and business results for the fourth quarter and full year ending Dec. 31, 2023. The financial report included full-year 2023 revenue of $13.1 million, a 76% increase over the prior year and an increase over the full-year 2023 revenue guidance as well as Q4 2023 product revenue of $2.5 million, an increase of 152% compared to the same period in 2022; the company's full-year gross margin was 27% with a Q4 2023 gross margin of 54%. Business highlight for the company included its continued partnership withKoito Manufacturing Co. Ltd., a final round of sourcing discussions with a top 10 global automotive OEM for long-range lidar and a request for quote ("RFQ") from a top 3 global automotive OEM. In addition, the company continued lidar shipments to major airports through its partnership with the Indoor Lab, completed a significant development milestone for a major autonomous industrial vehicles OEM using its Nova product and unveiled Cepton Ultra, the next-generation of high-performance long-range lidar with the smallest form factor in the industry to date. "We are building upon our extensive OEM project experience in commercializing automotive grade lidars, in collaboration with our tier 1 partner, to pursue sourcing wins with global OEMs," said Cepton cofounder and CEO Jun Pei in the press release. "At CES 2024, we showcased our best-in-class, next-generation product, Cepton Ultra, demonstrating our leadership in lidar innovation."

To view the full press release, visit

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.3598, off by 0.607735%, on 113,983 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.229/$4.40.

Recent News

Mountain Top Properties Inc. (OTC: MTPP)

The QualityStocks Daily Newsletter would like to spotlight Mountain Top Properties Inc. (OTC: MTPP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in two April investor conferences, including the MedInvest Biotech & Pharma Investor Conference and the 14th annual LD Micro Invitational. CNS Pharmaceuticals CEO John Climaco will present at the one-day MedInvest Biotech & Pharma Investor event, which is scheduled for April 4, 2024; Climaco's presentation will begin at 4:25 p.m. ET. The presentation can be watched live on the company's website. Climaco will also present at the LD Micro Invitational, which will be held April 9, 2024; his presentation will begin at 1 p.m. ET.

To view the Micro Invitational presentation, visit

To view the full press release, visit

Mountain Top Properties Inc. (OTC: MTPP) is a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships. The company specializes in property management, property technology (“PropTech”) and real estate redevelopment.

Mountain Top Properties was incorporated in 1990 and is based in Liverpool, New York, with offices in Sag Harbor, New York.


The company’s flagship subsidiary is Mountain Top Realty Inc., the managing partner of its first real estate fund focused on residential redevelopment in the prestigious and storied Hamptons, New York, beachfront communities.

Mountain Top Properties is also the lead investor in blockchain-enabled industrial and warehouse flex space HQXpress, which services the warehousing, reverse logistics and liquidation markets.

The company is in negotiations for the addition of AI-powered technologies that promise to simplify real estate services, including purchasing and sales.

Mountain Top Capital Fund I LLC

Mountain Top Capital Fund I LLC is a New York limited liability company recently organized by affiliates of Mountain Top Realty, manager of the fund. Through this fund, Mountain Top Realty will leverage the company’s experience, market conditions and industry relationships to capitalize on real estate projects as they arise.

This partnership will be focused on waterfront or water view properties in the Hamptons. The Hamptons market has historically remained strong and continues to set new highs year over year.

The fund has partnered with On Site Builder Construction Co. Inc., which is managed by Joseph Kelley, who, for over 40 years, has continued to build the highest quality architecturally designed custom houses, varying in style from classic to ultra-modern, in the Hamptons. Several houses he has built are showcased in books and magazines and featured across various forms of digital and social media. His assembled team of skilled subcontractors are among the finest skilled craftsmen in their various fields of expertise.

Mr. Kelley has built over 60 custom homes in this market and has the unique distinction of building the most expensive house sold in Sag Harbor in 2014, which sold for $31,750,000; the most expensive house in the Hamptons in 2019, which first sold for $27,500,000 in 2017 and later was renovated and re-traded for $39,250,000; and the most expensive house sold in the Hamptons in 2022, which sold with the neighboring house for $118,500,000. Mr. Kelley’s portfolio of projects is valued at over $400,000,000. Although he has historically worked as a custom home builder, he would like to shift from providing a service to now providing a finished product in this market.

Market Opportunity

Mountain Top Capital Fund I has a target to raise $75 million to acquire, renovate and remarket Hamptons waterfront or water view properties. The fund has secured debt capital commitments for 70% of the acquisition costs and 100% of the construction costs and will use $10 million to leverage strategic waterfront opportunities in and around the Hamptons.

Profits from each project will be distributed upon the sale of the project, which is anticipated every 15 to 18 months, with a target of a minimum return on investment of 20% to 30% per transaction.

The company anticipates the fund’s Hamptons projects will be followed up by several other funds targeting additional high-end markets.

Management Team

Beau Kelley is CEO, President, CFO and Director of Mountain Top Properties.

Mountain Top Properties Inc. (OTC: MTPP), closed Monday's trading session at $0.0395, up 31.6667%, on 3,056 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0085/$0.1898.

Recent News

Life Electric Vehicles Holdings Inc. (OTC: LFEV)

The QualityStocks Daily Newsletter would like to spotlightFathom Life Electric Vehicles Holdings Inc. (OTC: LFEV) .

Life Electric Vehicles Holdings Inc. (OTC: LFEV) (d/b/a Life EV Group), along with its subsidiaries, is a developer, manufacturer and distributor in the light electric vehicle industry. The company’s business model focuses on the launch, acquisition and consolidation of multiple brands of e-bikes, e-trikes, e-scooters and light EVs with the aim of positioning itself as an industry leader for the American micro-mobility market.

The light electric vehicle industry, mainly e-bikes, is fast becoming a leading form of EV sales in the U.S. and Europe. In addition to offering ready-to-ride electric vehicles, Life EV Group intends to distribute individual components, including motors, batteries, chargers, controllers and EV parts, to third party manufacturers in both the U.S. and worldwide.

The company’s first acquisition was completed in 2023 with a 40% equity stake in LEV Manufacturing Inc., a related company and American manufacturer of e-bikes. LEV Manufacturing’s assembly utilizes free-trade zone processes with a U.S. Certificate of Origin, eliminating middle layer costs and resulting in cost-effective production and lower MSRPs.

LEV Manufacturing recently completed the acquisition of Serial 1 Cycle Company LLC. Serial 1 is an e-bike maker founded by U.S. motorcycle manufacturer Harley-Davidson in 2018 and spun off as an independent brand in 2020. The acquisition positions Serial 1 for even greater success and long-term growth.

Life EV Group is headquartered in Deerfield Beach, Florida.

Market Opportunity

An analysis from Mordor Intelligence, a market research and advisory firm, estimates the e-bike market to be worth $34.98 billion in 2024 and projects it will expand to reach a value of $51.78 billion by 2029, representing a CAGR of 8.16% during the forecast period.

Mordor attributes forecast market growth primarily to the increasing adoption of electric bikes as a mode of daily transportation around the world. The market is seeing an upsurge in unit sales based on their attractive consumer characteristics, including health benefits, affordability and convenience.

The North American electric bike market is growing as the preference for low-speed two- and three-wheelers has increased in recent years. Various bike-sharing operators are including electric bikes in their fleets, which is expected to support the sales growth of these bikes in the near future.

Management Team

Robert Provost is the CEO of Life EV Group. He was Founder and CEO of Prodeco Technologies, a maker of e-bikes and e-bike parts and accessories. He also serves as President and CEO of LEV Manufacturing Inc. He is Chairman of the board for Serial 1 Cycle Company.

Daniel Del Aguila is COO at Life EV Group. He co-founded Prodeco Technologies and serves as COO of LEV Manufacturing Inc.

Ivan Drusc is CFO at Life EV Group. He is a seasoned accounting and finance professional with a proven track record in industries from insurance to IT and property management. He has served as a key player in businesses ranging in size from startups to publicly traded global companies. He has experience in cost reduction, risk mitigation, IT and ERP systems, outsourcing and restructuring. He is a graduate of the University of Akron with a bachelor’s degree in accounting.

Life Electric Vehicles Holdings Inc. (OTC: LFEV), closed Monday's trading session at $0.65, even for the day. The average volume for the last 3 months is 138 and the stock's 52-week low/high is $0.25/$1.25.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.


MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Monday's trading session at $0.058, even for the day. The average volume for the last 3 months is 2,046 and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Friday's trading session at $10.83, up 4.4359%, on 81,689 volume with 697 trades. The average volume for the last 3 months is 269,609 and the stock's 52-week low/high is $2.33999991/$20.0783996.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.